Study evaluates use of inhaled saline for young children with cystic fibrosis

Public release date: 20-May-2012
[ | E-mail | Share ]

Contact: Mary Guiden
mary.guiden@seattlechildrens.org
206-987-7334
JAMA and Archives Journals

Margaret Rosenfeld, M.D., M.P.H., of Seattle Children's Hospital, and colleagues conducted a study to examine if hypertonic saline would reduce the rate of pulmonary exacerbations in children younger than 6 years of age with cystic fibrosis (CF). Inhaled hypertonic saline is recommended as therapy for patients 6 years or older with CF, but its efficacy has not been evaluated in patients younger than 6 years.

In the randomized trial, the active treatment group (n = 158) received 7 percent hypertonic saline and the control group (n = 163) received 0.9 percent isotonic saline, nebulized (dispensed in a fine mist) twice daily for 48 weeks. The researchers found that the average pulmonary exacerbation rate was similar between both groups. "Hypertonic saline did not reduce the rate of pulmonary exacerbations in these young children. In addition, hypertonic saline did not demonstrate any significant effects on secondary end points including weight, height, respiratory rate, oxygen saturation, antibiotic use, or parent report of respiratory signs and symptoms."

###

(doi:10.1001/JAMA. 2012.5214. Available pre-embargo to the media at http://media.jamanetwork.com)

To contact Margaret Rosenfeld, M.D., M.P.H., call Mary Guiden at 206-987-7334 or email mary.guiden@seattlechildrens.org.

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Public release date: 20-May-2012
[ | E-mail | Share ]

Contact: Mary Guiden
mary.guiden@seattlechildrens.org
206-987-7334
JAMA and Archives Journals

Margaret Rosenfeld, M.D., M.P.H., of Seattle Children's Hospital, and colleagues conducted a study to examine if hypertonic saline would reduce the rate of pulmonary exacerbations in children younger than 6 years of age with cystic fibrosis (CF). Inhaled hypertonic saline is recommended as therapy for patients 6 years or older with CF, but its efficacy has not been evaluated in patients younger than 6 years.

In the randomized trial, the active treatment group (n = 158) received 7 percent hypertonic saline and the control group (n = 163) received 0.9 percent isotonic saline, nebulized (dispensed in a fine mist) twice daily for 48 weeks. The researchers found that the average pulmonary exacerbation rate was similar between both groups. "Hypertonic saline did not reduce the rate of pulmonary exacerbations in these young children. In addition, hypertonic saline did not demonstrate any significant effects on secondary end points including weight, height, respiratory rate, oxygen saturation, antibiotic use, or parent report of respiratory signs and symptoms."

###

(doi:10.1001/JAMA. 2012.5214. Available pre-embargo to the media at http://media.jamanetwork.com)

To contact Margaret Rosenfeld, M.D., M.P.H., call Mary Guiden at 206-987-7334 or email mary.guiden@seattlechildrens.org.

---

[ | E-mail | Share ]

?

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

elf on the shelf 2012 grammy nominations stephen sondheim los angeles news grammys 2011 mike leach mike leach